柳氮磺吡啶与甲氨蝶呤治疗银屑病性关节炎疗效  

Therapeutic Effect of Sulfasalazine Combined with Methotrexate in the Treatment of Psoriatic Arthritis

作　　者：冼伟福 成世立[1] 邹进益 Xian Weifu(Xinyi People's Hospital,Maoming 525300)

机构地区：[1]信宜市人民医院,茂名525300

出　　处：《数理医药学杂志》2019年第3期418-419,共2页Journal of Mathematical Medicine

摘　　要：目的:研究分析柳氮磺吡啶联合甲氨蝶呤治疗银屑病性关节炎的效果。方法:选取2016年7月～2018年6月某院23例银屑病性关节炎患者设为观察组,采用柳氮磺吡啶联合甲氨蝶呤治疗,另选取同期23例银屑病性关节炎患者设为对照组,仅采用甲氨蝶呤治疗,比较两组患者治疗效果及用药安全性。结果:观察组患者治疗获得总有效率为95.7%,对照组患者治疗总有效率为65.2%,观察组疗效明显优于对照组(P<0.05);对照组患者不良反应发生率为21.7%,观察组患者不良反应发生率为26.1%,两组间不良反应发生率差异统计并不存在统计学意义(P>0.05)。结论:柳氮磺吡啶联合甲氨蝶呤治疗银屑病性关节炎的临床疗效确切,要更优于单一采用甲氨蝶呤的治疗效果,且治疗安全性相当,是临床可首选的治疗手段。Objective:To observe the effect of sulfasalazine combined with methotrexate in the treatment of psoriatic arthritis.Methods:23 patients with psoriatic arthritis in a hospital from July 2016 to June 2018 were selected as the observation group.The observation group was treated with sulfasalazine and methotrexate.In addition,23 patients with psoriatic arthritis in the same period were selected as the control group,and only methotrexate was used for treatment.The therapeutic effects and medication safety of the two groups were compared.Results:The total effective rate was 95.7%in the observation group,higher than the control group with 65.2%(P<0.05).The incidence of adverse reactions was 21.7%in the control group and 26.1%in the observation group.The difference in the incidence of adverse reactions between the groups had no statistical significance(P>0.05).Conclusion:The clinical efficacy of sulfasalazine combined with methotrexate in the treatment of psoriatic arthritis is better than that of single methotrexate,and it is safe in treatment.It is the first choice for clinical treatment.

关 键 词：柳氮磺吡啶 甲氨蝶呤 银屑病性关节炎 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]